NCT04661397View on ClinicalTrials.gov

A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

July 2, 2021

Study Completion Date

July 2, 2021

Conditions
Healthy
Interventions
DRUG

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC

Participants will receive a single dose of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC tablet orally as per assigned treatment sequence.

DRUG

Darunavir

Participants will receive a single dose of Darunavir orally as per assigned treatment sequence.

DRUG

Emtricitabine/Tenofovir Alafenamide

Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.

DRUG

Cobicistat

Participant will receive a single dose of Cobicistat tablet orally as per assigned treatment sequence.

Trial Locations (1)

9728 NZ

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04661397 - A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents | Biotech Hunter | Biotech Hunter